Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Diabetes

Journal Scan / Research · February 18, 2016

Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients With Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Keith Ferdinand MD, FACC, FAHA, FNLA, FASH

The Lancet Diabetes & Endocrinology
The Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients With Type 2 Diabetes: A Meta-Analysis of Individual Patient Data
Lancet Diabetes Endocrinol 2016 Feb 08;[EPub Ahead of Print], N Sattar, D Preiss, JG Robinson, CS Djedjos, M Elliott, R Somaratne, SM Wasserman, FJ Raal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated